Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...
Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan ...
Management holds 11th Annual ESG Investor Virtual Event on December 9 at 10 am. NVS ).webcasts.com/starthere.jsp?ei=1689776&tp_key=9312b9a422′ target= ‘_blank’; rel=’nofollow’>Webcast Link Discover ...
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...
Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major ...
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...
Novartis suffered a legal setback on Wednesday as the company failed to persuade a U.S. appeals court to halt MSN ...
MSN Pharma was given FDA approval for its Entresto (sacubitril and valsartan) generic on 24th July, prompting a legal ...
Novartis Bangladesh Limited (“NBL”) announced on Thursday that the agreement by Novartis AG to transfer its shares in NBL to ...
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset ...
The US court's decision had an adverse impact of Divi's Labs' stock as the Indian company has a CDMO pact with Novartis for ...